Ken Griffin Phathom Pharmaceuticals, Inc. Call Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	SELL	$8.97 - $12.05 $144,417 - $194,005	-16,100 Reduced 86.56%	2,500 $25,000
Q1 2024 May 15, 2024	BUY	$6.21 - $11.05 $46,575 - $82,875	7,500 Added 67.57%	18,600 $197,000
Q4 2023 Feb 14, 2024	SELL	$6.99 - $10.71 $19,572 - $29,988	-2,800 Reduced 20.14%	11,100 $101,000
Q3 2023 Nov 14, 2023	SELL	$10.26 - $15.7 $257,526 - $394,070	-25,100 Reduced 64.36%	13,900 $144,000
Q2 2023 Aug 14, 2023	SELL	$7.28 - $14.32 $34,216 - $67,304	-4,700 Reduced 10.76%	39,000 $558,000
Q1 2023 May 15, 2023	BUY	$6.19 - $12.36 $224,697 - $448,668	36,300 Added 490.54%	43,700 $312,000
Q4 2022 Feb 14, 2023	SELL	$9.18 - $11.53 $785,808 - $986,968	-85,600 Reduced 92.04%	7,400 $83,000
Q3 2022 Nov 14, 2022	SELL	$6.46 - $12.11 $21,964 - $41,174	-3,400 Reduced 3.53%	93,000 $1.03 Million

126

59.6M

467K

34.9K

Ticker PHAT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,175,200
Market Cap $705M
Description
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.